SAB Biotherapeutics (SABS) Operating Margin (2021 - 2024)
SAB Biotherapeutics' (SABS) quarterly Operating Margin came in at 8726.26% in Q4 2024, down 253836.0% YoY from N/an in Q1 2024, and down 125.08% on a QoQ basis from 3876.95% in Q2 2024.
SAB Biotherapeutics (SABS) Operating Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of Operating Margin data on file, last reported at 8726.26% in Q4 2024.
- Quarterly Operating Margin fell 253836.0% year-over-year to 8726.26% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 3244.87% (down 154432.0% YoY) and the FY2024 annual result came in at 3244.87%, down 154432.0% from the prior year.
- Operating Margin slipped to 8726.26% in Q4 2024, from 3876.95% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 4.81% in Q1 2021 to a low of 8726.26% in Q4 2024.
- A 4-year average of 2007.32% and a median of 363.74% in 2022 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2023 — Operating Margin tumbled 747037 bps — and 2024, when it soared 369644 bps.
- Tracing SABS's Operating Margin over 4 years: stood at 66.41% in 2021, then plunged by 448 bps to 363.74% in 2022, then tumbled by 1601 bps to 6187.9% in 2023, then sank by 41 bps to 8726.26% in 2024.
- The last three Operating Margin figures came in at 8726.26% (Q4 2024), 3876.95% (Q2 2024), and 1205.9% (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -8,726.26% |
| Jun 30, 2024 | -3,876.95% |
| Mar 31, 2024 | -1,205.90% |
| Dec 31, 2023 | -6,187.90% |
| Sep 30, 2023 | -420.00% |
| Jun 30, 2023 | -7,573.40% |
| Mar 31, 2023 | -1,273.79% |
| Dec 31, 2022 | -363.74% |
| Sep 30, 2022 | -217.49% |
| Jun 30, 2022 | -103.03% |
| Mar 31, 2022 | -56.83% |
| Dec 31, 2021 | -66.41% |
| Sep 30, 2021 | -27.18% |
| Jun 30, 2021 | -15.77% |
| Mar 31, 2021 | 4.81% |